• Femasys doubled actively enrolling U.S. sites to 12 for its FemBloc FINALE pivotal trial in non-surgical permanent birth control.
• No trial results were presented; the expanded enrollment is intended to support completion of the U.S. study and an FDA filing.
• FemBloc is positioned as an office-based alternative to surgical sterilization, aiming to avoid anesthesia, incisions, and recovery time.
• Europe has already cleared FemBloc, enabling post-market real-world evidence collection to complement the U.S. pivotal dataset.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610140900PRIMZONEFULLFEED9845283) on October 14, 2026, and is solely responsible for the information contained therein.